Piramal Pharma Ltd Q2 FY26 Concall Decoded: “Flat growth and fuller explanations — a pharma sermon with many footnotes.”
1. Opening Hook
If resilience had a flavor, Piramal Pharma just served a half-cooked one — slow orders, slower optimism, and a spoonful of guidance moderation. Nandini Piramal’s calm voice masked the fact that the CDMO engine is coughing on customer destocking fumes. Yet, management insists “FY30 is still sacred.” Ah yes, faith can move molecules, if not margins.
As the Bhagavad Gita reminds us — “You have the right to perform your duty, but not to the fruits thereof.” Piramal surely took that literally this quarter. Stick around; things get spicier when the analysts start poking.
2. At a Glance
Revenue ₹2,044 Cr (↓ YoY) – Customer destocking called the shots; demand ghosted.
EBITDA Margin 11% – Leaner than expected; optimization only cushioned the fall.
Net Debt ₹3,971 Cr – Debt diet working; down ₹228 Cr via working-capital yoga.
CDMO Revenue ₹1,044 Cr – Hit by large order pause; prayers sent to FY27.
Consumer Healthcare +15% – Lacto Calamine glowing brighter than EBITDA.
Full-year Guidance Flat – “Flat” is the new “steady” when patience is the strategy.
3. Management’s Key Commentary
“Revenue declined due to inventory destocking from one large CDMO customer.” (Translation: One customer sneezed, and we caught the fiscal flu 😷.)
“EBITDA margin moderated to 11%—cost control partly mitigated the hit.” (They trimmed fat but still lost muscle.)
“We reduced net debt by ₹228 Cr; balance sheet remains disciplined.” (When growth hides, the CFO shows up with scissors.)
“We’ve seen uptick in biopharma funding and M&A; early signs of recovery.” (Translation: Hope is not a metric, but we’ll take it.)
“We are investing $90M in ADCelerate program across Lexington and Riverview.” (The future is expensive but photogenic.)
“Consumer Healthcare grew 15%, with e-commerce now 24% of sales.” (Apparently, Lacto Calamine sells faster online than CDMO contracts offline 🧴.)
“FY30 goal of $2B revenue and 25% margin remains intact.” (Because every pharma story needs a messiah year.)
